- Retatrutide activates GIP, GLP-1 and glucagon receptors simultaneously.
- Reduces appetite, enhances insulin secretion, increases energy expenditure.
- Clinical trials demonstrated up to 24% weight reduction with prolonged high-dose use.
- May be recommended for patients with obesity, type 2 diabetes, metabolic syndrome and fatty liver disease (NAFLD/MASLD).
- Still investigational, to be used under specialist supervision.
Array
(
[actionUrl] => [[+assetsUrl]]action.php
[form] => admin@sacred-leaves.com,idrees@sacred-leaves.com,info@sacred-leaves.com
[formSelector] => ajax_form
[frontend_css] => [[+assetsUrl]]css/default.css
[frontend_js] => [[+assetsUrl]]js/default.js
[objectName] => AjaxForm
[snippet] => FormIt
[hooks] => email
[emailTpl] => tpl.simple-email
[emailSubject] => Сообщение с сайта
[emailTo] => verfut@yandex.ru
[validate] => username:required, tel:required
[validationErrorMessage] => В форме содержатся ошибки!
[successMessage] => Сообщение успешно отправлено
)